PR Newswire Asia's news > Medical/Pharmaceuticals

 |   Title only   |   Print    Next page > 
     
Eyes that photosynthesise: NUS scientists plant a cure for dry eye disease
A nanosized extract of the plant thylakoid grana — the molecular engine behind photosynthesis — is transplanted into the eye's corneal cells, producing a key protective molecule when exposed to ambient ...
2026-05-16T    Education   Health Care/Hospital   Higher Education   Medical/Pharmaceuticals 
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability to date . Dr. Coulie brings more than 25 years of international biopharma leadership ...
2026-05-15T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Malaysia Healthcare Week Myanmar 2026 Opens in Yangon with Leading Hospitals Showcasing Specialised Care for Myanmar Patients
YANGON, Myanmar and KUALA LUMPUR, Malaysia , May 15, 2026 /PRNewswire/ -- Malaysia Healthcare Week Yangon 2026 is officially launched today at Park Royal Yangon, bringing together leading Malaysian ...
2026-05-15T    Health Care/Hospital   Medical/Pharmaceuticals   Travel   Trade show news 
Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced solid tumor patients ...
2026-05-15T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
HONG KONG , May 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled ...
2026-05-15T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Ozelle Wins German Innovation Award Gold for Advancing the Fourth Generation of Hematology Analysis
BERLIN , May 15, 2026 /PRNewswire/ -- Ozelle has received a Gold Award at the German Innovation Award , one of Germany's leading innovation honors, for its EHBT-50 Mini Lab Multi-Functional Analyzer. ...
2026-05-15T    Computer/Electronics   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Herbalgy Trophy & "Goal-Getter Giveaway" - A Triumphant Return
Spend HK$180 Unlocks Your Shot at Over HK$1M in Match Tickets – 1,000 Tickets to Chelsea FC vs. Juventus at Kai Tak Buy More, Enter More ...
2026-05-15T    Entertainment   Health Care/Hospital   Medical/Pharmaceuticals 
SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of 'SNB-101'
SEONGNAM, South Korea , May 15, 2026 /PRNewswire/ -- SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing ...
2026-05-15T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
NeuroEndocrine Cancer Australia unveils new website and digital lifeline
NeuroEndocrine Cancer Australia (NECA) has launched a fully updated digital platform designed to improve how the 31,000 Australians affected by neuroendocrine cancer (NETs) access support, information, ...
2026-05-15T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
POMDOCTOR LIMITED Announces Fiscal Year 2025 Financial Results
GUANGZHOU, China , May 15, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases ...
2026-05-15T    Health Care/Hospital   Medical/Pharmaceuticals 
  Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.